Artificial Organ And Bionics Market Size, Share, Opportunities, And Trends By Product (Artificial Organ, Artificial Bionics), By Technology (Mechanical Bionics, Electronic Bionics), By End-User (Hospitals, Clinics, Others), And By Geography - Forecasts From 2023 To 2028

The artificial organ and bionics market is estimated to grow at a CAGR of 7.87% during the forecast period.

Artificial organs and bionics are cutting-edge fields of biomedical engineering that aim to develop and integrate artificial devices into the human body to replace or enhance natural biological functions. The increasing prevalence of chronic diseases such as kidney failure or heart failure along with technological advancements and the growing elderly population are major growth drivers of the artificial organ and bionics market.

Increasing Prevalence of Chronic Diseases

The prevalence of chronic diseases such as heart failure, kidney failure, diabetes, and neurodegenerative conditions is on the rise globally. Artificial organs and bionics offer potential solutions for managing and treating these conditions, providing patients with a better quality of life and improved survival rates. According to the National Kidney Foundation, chronic kidney disease (CKD) affects 10% of the global population, and millions die each year. Moreover, heart failure affects more than 64 million people worldwide as per the World Heart Federation.

Aging Population

The world's population is aging, leading to a higher incidence of age-related diseases and conditions. The growing aging population drives the accelerated need for artificial organs thereby boosting the artificial organ and bionics market. For instance, one in every five males and one in every four women worldwide aged 65 to 74 had CKD, according to the National Kidney Foundation estimates. Moreover, in 2020, the number of persons aged 60 and more exceeded the number of youngsters under the age of five and between 2015 and 2050, the fraction of the global population over the age of 60 will nearly double, from 12% to 22% according to the WHO.

Technological Advancements

Rapid advancements in biotechnology, material sciences, and medical device technology have led to the development of more sophisticated and effective artificial organs and bionic devices. These advancements have made it possible to create devices with better biocompatibility, longer lifespan, and enhanced functionalities, driving the adoption of these technologies in clinical practice thereby propelling the artificial organ and bionics market. Advances in 3D bioprinting have proven to be critical in organ transplantation since it is utilized to produce artificial organs. As it reduces the danger of organ rejection, 3D bioprinting is becoming increasingly popular.

Government and Institutional Support

Regulatory agencies such as the U.S. FDA and the European Medicines Agency (EMA), have been supportive of innovations and expediting the approval process for certain devices, thereby aiding the artificial organ and bionics market growth. For instance, the Beta Bionics iLet ACE Pump and iLet Dosing Decision Software were approved by the US Food and Drug Administration for patients aged six and up with type 1 diabetes in May 2023. Moreover, collaborations between academia, research institutions, and private companies have fueled innovation in the artificial organ and bionics market. For example, the VANGUARD project, financed by the European Commission aims to create a vascularized and immune-protected bio-artificial pancreas for transplantation into Type I diabetes patients.

Higher Incidence of Road Accidents

Road accidents can cause severe injuries that may lead to organ failure or irreparable damage. In such cases, organ transplantation may become necessary for the survival of the affected individuals.  Therefore, the higher road accident rate is expected to accelerate the artificial organ and bionics market. For instance, according to the WHO, road traffic accidents cost several nations roughly 3% of their gross domestic product (GDP). Additionally, according to India's Ministry of Road Transport and Highways, 412,432 road accidents occurred across the country in 2021, affecting 3,84,448 persons.

Organ Shortage and Transplantation Challenge

The demand for organ transplants far exceeds the available supply of donor organs leading to long waiting lists and a significant organ shortage. Artificial organs serve as a bridge to transplantation or as a permanent solution for patients who are not suitable candidates for organ transplantation. For instance, according to the Human Resources and Services Administration (HRSA), there were more than 106,108 persons on the national waiting list in the United States in 2022. According to the HRSA, a person is added to the transplant waiting list in the United States every nine seconds, thereby increasing demand for artificial medical devices.

Restraints in the Market

The artificial organ and bionics market has experienced growth and development however some restraints or challenges can impact its expansion. For example, ensuring the biocompatibility and long-term safety of artificial organs and bionics is a significant challenge. The immune response, risk of infection, and potential for device failure remain important factors that need to be addressed. Additionally, many artificial organs and bionics have a finite lifespan and may require replacement or maintenance, which can add to the overall cost and complexity of managing the condition.

North America is Expected to Grow Considerably

North America is expected to hold a significant share of the artificial organ and bionics market during the forecast period. The factors attributed to such a share are the rising kidney diseases, technological advancements, government support, and rising healthcare expenditure. For instance, as of 2021, approximately 808,000 individuals in the United States were diagnosed with end-stage kidney disease (ESKD). Among them, 69% of patients were receiving dialysis treatment, while the remaining 31% had undergone kidney transplant procedures as per the NIDDK report. Moreover, treatment for renal failure takes 6.7% of the overall Medicare expenditure to provide care for fewer than 1% of the insured population in the US.

Major Market Players

• Zimmer Biomet is a global medical device company that focuses on designing, manufacturing, and marketing orthopaedic reconstructive products. It provides shoulder systems such as the Bigliani/Flatow® Complete Shoulder, Anatomical Shoulder™ System, Trabecular Metal™ technology, and Oxford Partial Knee System, among others.
• Abiomed Inc., a US-based medical technology company specializes in developing advanced medical devices focused on circulatory support and heart recovery. One of Abiomed's notable products is the Impella® line of percutaneous heart pumps which are designed to provide temporary circulatory support for patients with severe heart conditions.

Key Market Developments

• In April 2023, the US organ transplant system entered into a partnership with MIT on an AI-driven algorithm framework which was launched in March of the same year. This framework known as continuous distribution aims to make organ transplants more equitable with faster access to life-saving organisms.
• In January 2022, IIT-Kanpur initiated a project aimed at creating an innovative artificial heart with advanced capabilities. The project involves collaborations with several hospitals in India and is led by a team of experienced innovators carefully chosen for their expertise.

Segmentation:

• By Product
  • Artificial Organ
  • Artificial Bionics
• By Technology
  • Mechanical Bionics
  • Electronic Bionics
• By End-User
  • Hospitals
  • Clinics
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. ARTIFICIAL ORGAN AND BIONICS MARKET, BY PRODUCT

5.1. Introduction

5.2. Artificial Organ

5.3. Artificial Bionics

6. ARTIFICIAL ORGAN AND BIONICS MARKET, BY TECHNOLOGY

6.1. Introduction

6.2. Mechanical Bionics

6.3. Electronic Bionics

7. ARTIFICIAL ORGAN AND BIONICS MARKET, BY END-USER

7.1. Introduction

7.2. Hospitals

7.3. Clinics

7.4. Others

8. ARTIFICIAL ORGAN AND BIONICS MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES 

10.1. Zimmer Biomet

10.2. Medtronic

10.3. Abiomed Inc.

10.4. Sonova

10.5. Boston Scientific Corporation

10.6. Ekso Bionics

10.7. Edward Lifesciences Corporation

10.8. Berlin Heart

10.9. SynCardia

Zimmer Biomet

Medtronic

Abiomed Inc.

Sonova

Boston Scientific Corporation

Ekso Bionics

Edward Lifesciences Corporation

Berlin Heart

SynCardia